Items tagged with Pharma industry
Novartis receives US Patent and Trademark Office 2015 ‘Patents for Humanity’ award (post)
Novartis recognized for licensing agreement to provide promising drug candidates to the Global Alliance for TB Drug Development
Award recognizes ‘game changing’ innovations that have the potential to solve long-standing challenges in medicine, nutrition, sanitation, energy and living standards
Pharma offers view on how to slow antimicrobial resistance, boost research (post)
The threat of antimicrobial resistance is spreading and with it the urgency to find solutions to the matter. This week, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) provided its recommendations on how to slow down antimicrobial resistance and boost antibiotic research and development. In addition, the association organised a forum on the subject today.
Industry asks for clarity on LDC request to extend TRIPS pharma waiver (post)
Least developed countries (LDCs) at the World Trade Organization have requested that a waiver allowing them to not enforce intellectual property rights on pharmaceutical products be extended beyond its deadline of 1 January 2016. The brand pharmaceutical industry has published a statement that it supports access to medicines for LDCs but does not see the need for this extension as LDCs already benefit from a WTO waiver on all products until 2021.
Big pharma lacking in new antibiotic patents (post)
The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation in favour of rare disease drugs, according to a new study.
Leaked: What’s in Obama’s trade deal (post)
A recent draft of the Trans-Pacific Partnership free-trade deal would give U.S. pharmaceutical firms unprecedented protections against competition from cheaper generic drugs, possibly transcending the patent protections in U.S. law.
Resistance isn’t futile – how to tackle drug-resistant superbugs (post)
Low profit margins and the difficulty of finding new drugs has led to big pharma shutting down its antibiotics programmes. But now researchers are adopting new approaches to tackle drug-resistant superbugs
Council of Europe report upholds public health interests regarding the pharmaceutical industry (post)
UNAIDS has welcomed a report approved by the Parliamentary Assembly of the Council of Europe (PACE) on 29 September that recommends stronger regulation of the pharmaceutical sector to uphold public interest and prevent conflicts of interest.
IP clauses in FTAs should not go beyond TRIPS, generics manufacturers say (post)
Free trade agreements should include incentives for generic and biosimilar medicines, speakers said at a panel during the World Trade Organization Public Forum last week.
Response statement from Sandoz (post)
Due to stability issues impacting the intravenous tuberculosis treatment Rifampicin i.v., we have suspended production of this product. While the company recognizes that it is currently not able to supply the South African market and other markets worldwide with this specific formulation, Sandoz continues to supply Rifampicin in pill form to South African hospitals and healthcare providers. Patients with questions about their specific treatment should speak to a physician or healthcare professional.
LDCs be damned: USTR and Big Pharma seeks to eviscerate Least Developed Countries' insulation from pharmaceutical monopolies (post)
October 12, 2015 -- In November of 2001, at the height of the global AIDS pandemic, every WTO member country in the world, including the United States, voted unanimously in the Doha Declaration on the TRIPS Agreement and Public Health that WTO Least Developed Countries members should be granted an unconditional extension of any obligation to grant or enforce patents, data protections, or exclusive marketing rights on pharmaceutical products. These countries desperately needed access to affordable generic medicines and freedom from the pillage of Big Pharma's monopoly pricing. This sensible and humane transition policy was confirmed by votes of the WTO TRIPS Council and General Council in 2002.
Page 4 of 9 · Total posts: 0
←First 3 4 5 Last→